{"id":"NCT01307397","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Vemurafenib in Participants With Metastatic Melanoma","officialTitle":"An Open-Label, Multicenter Study to Assess the Safety of RO5185426 (Vemurafenib) in Patients With Metastatic Melanoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03-01","primaryCompletion":"2016-02-24","completion":"2016-02-24","firstPosted":"2011-03-02","resultsPosted":"2017-12-18","lastUpdate":"2017-12-18"},"enrollment":3219,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Malignant Melanoma"],"interventions":[{"type":"DRUG","name":"Vemurafenib","otherNames":["RO5185426, Zelboraf"]}],"arms":[{"label":"Vemurafenib","type":"EXPERIMENTAL"}],"summary":"This multi-center study evaluates the safety and efficacy of vemurafenib in participants with BRAF V600 mutation-positive, surgically incurable, and unresectable Stage IIIC or IV (American Joint Committee on Cancer \\[AJCC\\]) metastatic melanoma.","primaryOutcome":{"measure":"Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.0","timeFrame":"Baseline up to 28 days post end of treatment (maximum up to 46 months)","effectByArm":[{"arm":"Vemurafenib","deltaMin":52.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":280,"countries":["Albania","Argentina","Australia","Austria","Belgium","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Colombia","Croatia","Czechia","Denmark","Ecuador","Estonia","Finland","Germany","Greece","Hungary","India","Ireland","Israel","Italy","Latvia","Lithuania","Mexico","Netherlands","North Macedonia","Norway","Peru","Poland","Portugal","Romania","Russia","Serbia","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["30580112","24582505"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1114,"n":3219},"commonTop":["Arthralgia","Alopecia","Fatigue","Hyperkeratosis","Nausea"]}}